Company Intelligence
Roche is a Swiss multinational healthcare company that operates in two divisions: Pharmaceuticals and Diagnostics. It is the world's largest biotech company by revenue and the global leader in in-vitro diagnostics. Roche's unique combination of pharmaceutical and diagnostics capabilities underpins its strategy of personalized healthcare, where diagnostic tests guide treatment selection for individual patients. The company has leading franchises in oncology, immunology, neuroscience, and ophthalmology.
Pharmaceuticals & Life Sciences
Headquarters
Basel, Switzerland
Employees
~100,000
Revenue
CHF 58.7B (FY2024)
Fiscal Year End
December 31
Founded
1896
Current leadership team based on public filings and announcements.
Thomas Schinecker
CEO
Alan Hippe
CFO
Key events and changes that sales teams should know about.
Advanced its pharma-diagnostics integration strategy, leveraging companion diagnostics to guide treatment decisions in oncology and neuroscience, creating a differentiated model that competitors without diagnostics arms cannot replicate.
2025-01
Expanded personalized medicine programs with biomarker-driven clinical trials and companion diagnostic development, particularly in oncology where patient stratification is becoming a regulatory and commercial requirement.
2024-11
Progressed its Alzheimer's disease pipeline with next-generation anti-amyloid antibodies and tau-targeting therapies, positioning Roche in one of the largest potential pharmaceutical markets alongside Eli Lilly and Biogen.
2024-09
H1 2024 group sales grew 3% at constant exchange rates to CHF 29.8B, with Pharmaceuticals returning to growth after the COVID-era Ronapreve and Actemra headwind, and Diagnostics delivering steady mid-single-digit growth.
2024-07
Invested in AI-powered drug development platforms including computational biology, generative chemistry, and clinical trial design optimization, partnering with both internal data science teams and external AI companies.
2024-04
Roche's dual pharmaceuticals-diagnostics model is unique among major pharma companies and gives it a structural advantage in personalized medicine. As healthcare moves toward biomarker-driven treatment selection, Roche can develop both the drug and the companion diagnostic test simultaneously -- reducing time to market and creating stronger commercial moats. Vendors in the healthcare technology space should understand that Roche's diagnostics division (including legacy Genentech operations) is a massive buyer of laboratory equipment, data platforms, and analytical tools.
The Alzheimer's pipeline represents one of the highest-stakes bets in pharmaceutical history. If Roche's next-generation Alzheimer's therapies succeed, the commercial opportunity could exceed $10 billion annually. This pipeline investment drives significant R&D technology spending, including real-world evidence platforms, patient monitoring systems, and clinical trial management tools. Vendors serving the neuroscience clinical development space should track Roche's Alzheimer's program milestones closely.
Roche's December 31 fiscal year end follows the standard calendar year, but the company operates on European procurement practices that can differ significantly from US norms. Decision-making timelines tend to be longer, with more stakeholders involved in vendor selection. The Swiss franc denomination also means that currency fluctuations can impact purchasing power and budget allocations across Roche's global operations. Sales teams should factor in both the European business culture and currency dynamics when engaging with Roche procurement.
Key competitors based on market analysis and public filings.
Roche's fiscal year ends on December 31, following the standard calendar year. The company reports full-year results in late January or February and half-year results in July. Being a Swiss company, Roche reports in Swiss francs (CHF).
Roche generates approximately CHF 58.7 billion (roughly $67 billion) in annual revenue as of FY2024. The Pharmaceuticals division accounts for about 75% of revenue, with the Diagnostics division contributing the remaining 25%.
Roche is headquartered in Basel, Switzerland, where it was founded in 1896 by Fritz Hoffmann-La Roche. The company maintains major research and commercial hubs in Basel, South San Francisco (Genentech), Mannheim (diagnostics), and Shanghai, among other locations globally.
Genentech is a wholly owned subsidiary of Roche, acquired in 2009. Genentech operates as Roche's US pharmaceuticals business and maintains its own brand identity, South San Francisco campus, and research culture. Many of Roche's most important medicines (Herceptin, Avastin, Rituxan) were originally developed by Genentech.
Roche employs approximately 100,000 people across more than 100 countries. The workforce includes pharmaceutical researchers, diagnostics engineers, manufacturing specialists, and commercial teams, with major employment centers in Switzerland, the United States, Germany, and China.
See leadership changes, strategic initiatives, earnings insights, and buying signals for Roche — updated continuously.
